To see the other types of publications on this topic, follow the link: Control Data Corporation.
Journal articles on the topic 'Control Data Corporation'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Control Data Corporation.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Worthy, J. C. "Control Data Corporation: the Norris era." IEEE Annals of the History of Computing 17, no. 1 (1995): 47–53. http://dx.doi.org/10.1109/85.366514.
Full text
2
Grable‐Wallace, Lisa, Karen L. Johnston, and J. S. Risley. "Courseware review: Control data corporation: Physics 1 series." Physics Teacher 24, no. 3 (March 1986): 181–83. http://dx.doi.org/10.1119/1.2341977.
Full text
3
Jackson, Gary. "Contingency for Cost Control in Project Management: A Case Study." Construction Economics and Building 3, no. 1 (November 18, 2012): 1–12. http://dx.doi.org/10.5130/ajceb.v3i1.2906.
Full textAbstract:
This paper provides a case study of the application of cost management techniques for project management of capital works within a major Australian electricity corporation. Historical data was collected from the corporation's archived files to establish the performance status of completed capital works projects. A survey of the corporation's project staff was also conducted to determine the current usage of cost management techniques and further explore the findings of the historical data search.The research indicates a reluctance to utilise formal cost management procedures on minor projects, estimated to cost less than $1 million. The time constraints allocated to project management planning and the perceived cost to implement procedures were identified as contributing to the limited use of formal cost management on minor projects.The paper concludes that increased risk of poor budget performance is inevitable if formal cost control is not applied to capital works projects, and recommends informal risk assessment and cost contingency measures to address this issue.
4
Copithorne, Lawrence W. "La théorie des prix de transfert internes des grandes sociétés." Articles 52, no. 3 (June 25, 2009): 324–52. http://dx.doi.org/10.7202/800680ar.
Full textAbstract:
Abstract There is considerable merit in thinking of the modern multidivisional corporation as an economy within itself. There is an important similarity between the interaction of divisions within a corporation and the perfectly competitive economic model formulated by Leon Walras1. When we look at modern corporations from this viewpoint we discover that much of what we know in general equilibrium economics may have considerable application inside modern corporations. Some of our existing theorems help clarify distinctions between decentralization and central control in corporate management in the same way that they clarify the distinctions between the market economies and those that run by central decree. They help distinguish which divisions must be centrally managed and those which can be left to look after themselves. This viewpoint offers new insights too—that, for instance, the products transferred between divisions may quite logically have two transfer prices instead of one. This viewpoint also permits an easy synthesis of the existing literature on transfer pricing. While the transfer pricing issue is especially important for multinational and international corporations which transfer goods and services between divisions located in different countries, the principles generally apply to any multidivisional corporation. The purposes of this paper are to present a simple, but general analytic model of the multidivisional corporation, to use it to make a synthesis of the existing literature on transfer pricing, and to make some important new discoveries. 1 Léon Walras, Elements of Pure Economics, édité et traduit par W. Jaffe (London : George Allen and Unwin, 1954). Kenneth Arrow fait mention de cette similitude dans son article : « Optimization, Decentralization and Internal Pricing in Business Firms », Contributions to Scientific Research in Management, 9-18, Western Data Processing Centre, Los Angeles, University of California Press, 1961.
5
Kopcekova, Alena, Michal Kopcek, and Pavol Tanuska. "The Options of Using Data Mining Methods in Process Control." Applied Mechanics and Materials 693 (December 2014): 123–28. http://dx.doi.org/10.4028/www.scientific.net/amm.693.123.
Full textAbstract:
The term business intelligence (BI) represents the tools and systems that play a key role in the strategic planning process of the corporation. These systems allow a company to gather, store, access and analyze corporate data to aid in decision-making. Necessary fundamental definitions are offered and explained to better understand the basic principles and the role of this technology for a company management. The proposed article is logically divided into more sections, where the stages of basic research in the field of data mining are described gradually. This involves the definition of the technology and the list of main advantages and analytical methods incorporated in online analytical processing. Also some typical applications of above mentioned particular methods are introduced. The focus of this paper is to introduce the options of using the data mining methods on the control systems level within the hierarchical control systems model.
6
Kbiladze, David, and Shorena Metreveli. "THE SEARCH FOR MODERN METHODS FOR THE STATISTICAL QUALITY CONTROL OF SERVICES." Ekonomika 96, no. 2 (November 2, 2017): 102–9. http://dx.doi.org/10.15388/ekon.2017.2.11003.
Full textAbstract:
The countries with developed market economies have vast experience in using the statistical methods in running business. In this respect, the use of Six Sigma techniques and tools to control the output (service) quality is worthwhile. This technique, if introduced in Georgia, can be much beneficial for the businessmen. Different-profile companies use different statistical methods for the output (service) quality control. However, it is the Six Sigma techniques that yield the most pragmatic outputs. This tool enables the different-tier managers to rely not only on their intuition in making managerial decisions but also on the quantitative data obtained through the introduction of 6σ to their companies. The measures to search for the modern methods of introduction and better use of the 6σ concept seek to improve the output (production) quality of different sites of a corporation, while also meeting the changing demands of customer markets and shareholders. In the search of such measures, the authors of the present article attempted to examine the effect of the 6σ set beyond the limits of a corporation and, by considering the public opinion about the corporation, conduct the statistical control of the output (service) offered by the corporation to its clients. The pilot study, accomplished with this purpose by the authors of the article, together with their students, gave quite interesting results.
7
RathaKrishnan, L., and K. Santhy. "Globalisation, Multinational Corporation and Regional Development." Management and Labour Studies 27, no. 3 (July 2002): 191–98. http://dx.doi.org/10.1177/0258042x0202700304.
Full textAbstract:
Economic reforms introduced in India during 1991–92 had triggered the process of economic development in the country. It is from this period a structural shift occurred in Indian industry. The liberalization has also facilitated the Indian industries to sell their products throughout the world market. As the multinational Corporation normally own, manage, and control production, they can sell their products all over the world without much difficulty. After the announcement of globalization in India, the number of multinational corporation had increased from 389 (1981) to 2303 (1996), about six fold increase in 15 years period. The present paper examines how multinational corporations help regional development. A case study approach was followed. Both primary and secondary data were collected from the Whirlpool India Limited for a period of 18 years, starting from 1983–84 to 2000–01. By using simple growth rate and regression analysis this study found that there is a favourable shift in employment and infrastructure development in the region. After the establishment of the MNC, the region has received various benefits, namely employment, better road and transportation, local markets, hospitals, street lights, drinking water and other infrastructural facilities. Further more, this MNC has not harmed the growth of tiny and small scale industries in the region. In fact, the MNC has helped many small-scale industries to establish their industries in the region.
8
Chaula, Job Asheri, and Godfrey Weston Luwemba. "Security Control Assessment of Supervisory Control and Data Acquisition for Power Utilities in Tanzania." European Journal of Engineering Research and Science 5, no. 7 (July 13, 2020): 785–89. http://dx.doi.org/10.24018/ejers.2020.5.7.1429.
Full textAbstract:
The primary purpose of this research was to assess the adequacy and effectiveness of security control of the Supervisory Control and Data Acquisition (SCADA) communication network used by infrastructure companies. Initially, the SCADA networks were physically separated from other networks connected to the internet and hence assumed secure. However, the modern SCADA are now integrated with other network resulting in new security vulnerabilities and attacks similar to those found in traditional IT. Thus, it is important to reassess the security controls of the SCADA because it is operated in an open network environment. In this research, a case of the SCADA security controls in the power sector in Tanzania was assessed, whereby a specific SCADA implementation was studied. The data were gathered using observation, testing, interviews, questionnaire and documentation reviews. The results were analyzed using the Cyber Security Evaluation Tool (CSET) and checked for compliance based on the National Institute of Standards and Technology (NIST) and North America Electric Reliability Corporation (NERC) standards. The findings have shown that there exist security vulnerabilities both in security compliance of the standard and component-based vulnerabilities. Additionally, there is inadequate of audit and accountability, personnel security and system and information integrity. Also, for the component-based security compliance, the finding shows that identification and authentication, security management and audit and accountability. On the basis of the results, the research has indicated the areas that require immediate action in order to protect the critical infrastructure.
9
Talbot, Thomas R., Sheri Chernetsky Tejedor, Robert A. Greevy, Hayley Burgess, Mark V. Williams, Jayant K. Deshpande, Patsy McFadden, et al. "Survey of Infection Control Programs in a Large National Healthcare System." Infection Control & Hospital Epidemiology 28, no. 12 (November 2007): 1401–3. http://dx.doi.org/10.1086/523867.
Full textAbstract:
In light of consumers' and regulators' increasing focus on infection prevention, infection control practices and resources were surveyed at 134 hospitals owned by the Hospital Corporation of America. Infection control practices and resources varied substantially among hospitals, and many facilities reported difficulty acquiring the data they needed to report infection rates.
10
Mejia-Ruda, Edilberto, José Ferney Medina, Mauricio Mauledoux, Oscar Aviles Sanchez, and Max Suell Dutra. "Adaptive Control for Solar Photovoltaic Tracking System." Applied Mechanics and Materials 823 (January 2016): 377–82. http://dx.doi.org/10.4028/www.scientific.net/amm.823.377.
Full textAbstract:
This paper describes the behavior of adaptive control using the MIT rule for a polar aligned single axis tracking system, it´s for increase the efficiency of solar energy capturing compared to a polar fixed system, where the response of system is analyzed by simulation in Simulink – MATLAB® software. The data input for estimate the energy in the photovoltaic panels is the radiation data, that is obtained by weather station of the CAR (regional autonomous corporation) situated in the zone of study. The objective of the integration between the photovoltaic panel and the mechanics tracking system is to keep the perpendicular sunlight during the day. The MIT adaptive control tries to reduce possible errors, such a sun position data deviations, friction and environmental changes in the conventional solar tracking. This control was designed according to a typical polar aligned single axis tracker.
11
Brackenborough, Susie. "‘POUND FOOLISH PENNY WISE’ SYSTEM: THE ROLE OF ACCOUNTING IN THE IMPROVEMENT OF THE RIVER TYNE, 1800–1850." Accounting Historians Journal 30, no. 1 (June 1, 2003): 45–72. http://dx.doi.org/10.2308/0148-4184.30.1.45.
Full textAbstract:
The relationship between accounting and governmentality, and the increasing statutory regulation of companies by central government during the 19th century have attracted a great deal of attention from accounting historians. Conversely, accounting change within local authorities in this period has attracted far less attention. The paper examines the consequences of the increase in public accountability of local authorities in England and Wales in the context of the Newcastle Corporation, the body responsible for collecting and distributing the town's wealth. During the first half of the 19th century Newcastle Corporation was heavily criticized for neglecting the improvement of the River Tyne. The paper illustrates how the Newcastle Corporation and those opposed to it used accounting as a lobbying tool to promote their interests. Gallhofer and Haslam [2001, p. 29] showed how, in the late 19th century, “radical political activists” used accounting data through the medium of the press as an “emancipatory” practice. In many ways, the case of the improvement of the River Tyne during the early 19th century also reveals the use of accounting as an ‘emancipatory’ force by opposition groups. The paper finds that the Corporation used accounting data to justify inaction and the opposition used accounting data to promote its objectives. These contests resulted in the control of the River Tyne being taken from the Corporation and placed in the hands of a trust in 1850.
12
Moro Visconti, Roberto. "Public private partnerships, big data networks and mitigation of information asymmetries." Corporate Ownership and Control 14, no. 4 (2017): 205–15. http://dx.doi.org/10.22495/cocv14i4c1art3.
Full textAbstract:
Public Private Partnerships (PPP) represent an increasingly frequent investment pattern where composite stakeholders interact in joint initiatives. Alignment of interests and consequent composition of conflicts is driven by the business purpose of the shared corporation, represented by a private Special Purpose Vehicle (SPV) within a Project Financing (PF) investment package. Corporate governance implications go beyond the traditional contraposition between ownership and control, showing cooperative patterns where the value is co-created and distributed. Big data-driven networks represent a trendy issue that connects public and private stakeholders through digital platforms where data are shared in real time. Information asymmetries and governance concerns are consequently softened.
13
Yu, Sheng Wu, and Rui Jun Liu. "Performance Test Bench Development of Auto Transmission Control Mechanism." Applied Mechanics and Materials 80-81 (July 2011): 1160–64. http://dx.doi.org/10.4028/www.scientific.net/amm.80-81.1160.
Full textAbstract:
According to the capability require of the automotive transmission control mechanism（ATCM）, and entered into test method by the automotive accessory corporation and user，developed the performance test bench of ATCM，and introduce the makeup and function of test bench and control system. The test results showed that this test bench has many merits such as high test precision，stable anti-interfere capability，rapid fix test element，perfect function of man - computer dialogue，and see about history data facilely. It can provide reliable test method for the ATCM’s test and scientific reference for improve on ATCM.
14
Verstovsek, Srdan, Vikas Gupta, Jason R. Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, et al. "A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)." Blood 128, no. 22 (December 2, 2016): 3110. http://dx.doi.org/10.1182/blood.v128.22.3110.3110.
Full textAbstract:
Abstract Background:The Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been evaluated for patients with MF in the phase 3 COMFORT studies. In both trials, ruxolitinib prolonged OS, reduced splenomegaly, and improved MF-related symptoms and quality of life compared with controls. Here, we report the results of an exploratory pooled analysis of OS in the COMFORT studies at 5 years of follow-up. Methods: The double-blind COMFORT-I trial and the open-label COMFORT-II trial were randomized phase 3 studies that evaluated the safety and efficacy of ruxolitinib in patients with intermediate-2 (int-2) or high-risk primary MF (PMF), post-polycythemia vera MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF). The comparator was placebo in COMFORT-I and best available therapy (BAT) in COMFORT-II. The ruxolitinib starting dose was 15 or 20 mg twice daily based on baseline platelet counts (100-200 and >200 × 109/L, respectively); dose modifications were permitted for safety and efficacy. Patients were allowed to cross over to ruxolitinib from the control arm for progressive splenomegaly, defined as a ≥25% increase in spleen volume from baseline (COMFORT-I) or study nadir (COMFORT-II), or select protocol-defined progression events; crossover was mandatory following treatment unblinding in COMFORT-I. OS was a secondary endpoint in both studies and was evaluated in an intent-to-treat (ITT) analysis using a Cox proportional hazard model that estimated the treatment effect stratified by clinical trial and International Prognostic Scoring System (IPSS) risk. The crossover-corrected treatment effect was estimated using a rank-preserving structural failure time (RPSFT) method. Results: Overall, 528 patients were randomized: 301 to ruxolitinib (COMFORT-I, n=155; COMFORT-II, n=146) and 227 to placebo (n=154) or BAT (n=73). All ongoing patients in the control arms crossed over to ruxolitinib by the 3-year follow-up. Patient populations were similar between the two trials and their details were previously published. In the combined ruxolitinib group, 162 patients (53.8%) had high-risk MF and 139 (46.2%) had int-2 risk MF based on IPSS criteria. At the 5-year ITT analysis, 128 patients (42.5%) died in the ruxolitinib group compared with 117 (51.5%) in the control group. The risk of death was reduced by 30% with ruxolitinib compared with control (median OS: ruxolitinib, 63.5 mo; control, 45.9 mo; HR, 0.70; 95% CI, 0.54-0.91; P=0.0065; Figure A). After correcting for crossover using RPSFT, OS advantage was more pronounced for patients originally randomized to ruxolitinib (median OS: ruxolitinib, 63.5 mo; control, 27 mo; HR, 0.35; 95% CI, 0.23-0.59; Figure B). An analysis of OS censoring patients at the time of crossover also demonstrated that ruxolitinib prolonged survival compared with control (median OS: ruxolitinib, 63.5 mo; control, 28.3 mo; HR, 0.53; 95% CI, 0.36−0.78; P=0.0013; Figure C). Among all patients treated with ruxolitinib, those with lower-risk disease had longer survival compared with those with high-risk disease (median OS: int-2, not reached [estimated, 102 mo]; high-risk, 50 mo; HR, 2.86; 95% CI, 1.95-4.20; P<0.0001; Figure D). In a subgroup analysis, OS favored ruxolitinib compared with placebo for patients with int-2 or high-risk MF (data not shown). At 5 years, median OS appeared to favor patients with int-2 (n=58) or high-risk (n=89) PMF who were originally randomized to ruxolitinib compared with historical (Cervantes et al; J Clin Oncol 30:2981-2987) controls (int-2 PMF, not reached [estimated, 70 mo] vs 48 mo; high-risk PMF, 34 vs 27 mo); OS was longer among patients with int-2 vs high-risk PMF (P=0.0003). Subgroup analyses showed that ruxolitinib provided an OS advantage regardless of age (>65 or ≤65 y), sex, disease type (PMF, PPV-MF, PET-MF), risk status (int-2 or high), JAK2V617F mutation status, baseline spleen volume (>10 or ≤10 cm), anemia, white blood cell count (>25 or ≤25 × 109L), or platelet count (>200 or ≤200 × 109/L). Conclusion: Long-term treatment with ruxolitinib up to 5 years prolonged survival in patients with MF compared with BAT or placebo. Corrections for patients who crossed over to ruxolitinib suggested that the separation between ruxolitinib and control OS curves was primarily caused by a delay in ruxolitinib treatment. The results suggest that earlier treatment with ruxolitinib may provide a greater survival advantage for patients with MF. Disclosures Gupta: Incyte Corporation: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Mesa:Incyte: Research Funding; Ariad: Consultancy; Novartis: Consultancy; Celgene: Research Funding; CTI: Research Funding; Promedior: Research Funding; Galena: Consultancy; Gilead: Research Funding. Vannucchi:Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Kiladjian:AOP Orphan: Research Funding; Novartis: Research Funding. Cervantes:AOP Orphan: Membership on an entity's Board of Directors or advisory committees; Baxalta: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Sun:Incyte Corporation: Employment, Equity Ownership. Gao:Incyte Corporation: Employment, Equity Ownership. Dong:Novartis Pharmaceutical Corporation: Employment, Equity Ownership. Naim:Incyte Corporation: Employment, Equity Ownership. Gopalakrishna:Novartis Pharma AG: Employment, Equity Ownership. Harrison:Incyte Corporation: Honoraria, Speakers Bureau; Baxaltra: Consultancy, Honoraria, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; CTI Biopharma: Consultancy, Honoraria, Speakers Bureau; Shire: Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: travel, accommodations, expenses, Research Funding, Speakers Bureau.
15
Seifzadeh, Pouya. "Corporate controls, geographic dispersion, and their effect on corporate financial performance in related diversified corporations." Journal of Strategy and Management 10, no. 1 (February 20, 2017): 102–17. http://dx.doi.org/10.1108/jsma-10-2015-0079.
Full textAbstract:
Purpose Drawing on the literature on corporate diversification, the purpose of this paper is to shed light onto the influence of geographic dispersion on the effectiveness of control mechanisms in related diversified corporations. This research contends that control mechanisms implemented by corporations and the extent of geographic diversification play a role in the synergies expected from related diversification being realized. Design/methodology/approach This study uses OLS regression to analyze data collected through surveys from managers of 193 Iranian corporations and their 2,704 subsidiaries to examine the relationship between relatedness, corporate performance, geographic dispersion, and emphasis of strategic controls. Findings The author finds that a triple interaction effect between corporate strategy (diversification approach), controls mechanisms, and the extent of geographic diversification influences the overall performance of corporations. Findings of this research suggest that the positive effects of strategic controls in related diversified corporations are most when there is less geographic dispersion and will attenuate as corporations become more geographically disperse. Research limitations/implications The findings of this research, have contributed to the extant literature in several ways. First, the findings further establish the superiority of related diversification to unrelated diversification in achieving economic performance in corporations. The findings reveal that, ceteris paribus, the more relatedness between activities of subsidiaries in corporations exists, higher performance can be expected at the corporate level. Second, the findings show once more that to achieve the higher performance that results from synergies in related diversified corporations, emphasis of strategic controls play a crucial and important role. Third, the author find that although the emphasis of strategic controls in essential to realizing the potentials in related diversified corporations, greater geographic dispersion attenuates the positive effects expected from stricter enforcement of strategic control mechanisms. Practical implications An important consequence of findings of this research is that managers should be more aware of the implications of selecting the geographic location of the subsidiaries that they either acquire or establish. While the literature focusing on corporate diversification has mainly focused on the differences between related and unrelated diversification, this paper brings a new factor into light. Therefore, the findings of this research provide the author with a better understanding of the factors that define success or failure in achieving financial objectives of corporations. Originality/value There has been very little done to investigate the factors that influence effectiveness of strategic controls in related diversified corporation. Much of this shortcoming has resulted due to difficulties in measurement of strategic controls their operationalization in empirical studies. This study has taken a step to that direction and therefore, provides a more coherent and clear picture of the factors that influence the overall performance in corporations.
16
Hossen, Md Mansur. "Kitchen Market Monitoring in Bangladesh: A Study on Dhaka South City Corporation." Public Administration Research 7, no. 1 (April 25, 2018): 26. http://dx.doi.org/10.5539/par.v7n1p26.
Full textAbstract:
Dhaka City Corporation (DCC) is the former self-governing corporationwhich is associated with the task of running the affairs of the city of Dhaka . According to the Local Government Act (Amendment), 2011, it is the mandatory function of City Corporation to show the price chart of daily necessities in front of market. Sellers are bound to follow this price chart. It is the right of citizens to bargain with seller to follow this chart. DSCC (Dhaka South City Corporation) acts as a watchdog in the market to follow the price chart. But unfortunately, price chart do not exist in many markets of DSCC jurisdiction. Although sometimes price chart exit but it is not updated regularly. In Bangladesh, every marketing sphere is controlled by a financially powered group. They are also considered as syndicate. They control each and every movements of market. The kitchen market is not out of their black hand. Therefore, it is obvious that every classes of customer need to go there for their own daily essential commodities.The price of daily essential commodities imposed by DCC is not followed by the sellers. Imposed price of DCC is not effective for customer unawareness and their indifferent attitude. Most of the time, it is impossible to pursue the imposed price although Government and its related administration department want to control it. The objectives of the study is to conduct a survey on the Bazaar monitoring system of DSCC and the effectiveness of the corporation to monitor the prices of daily necessities in a kitchen market. This research is mainly qualitative in nature. A stratified sampling method is followed for conducting this research. Data is collected from both primary and secondary sources. The primary data has been collected from four kitchen market (Polashi Bazaar,Ananda Bazaar,New Market Bazaar and Hatirpool Bazaar) under DSCC jurisdiction. Secondary sources of data are books, internet, journals, DSCC’s acts, DSCC’s annual reports and reports of different research organizations concerned with Bazaar monitoring.
17
Shukla, Archana, and Anurag Tripathi. "Influence of Gender and Hierarchical Position on Interpersonal Relations at Work." Psychological Reports 74, no. 3_suppl (June 1994): 1280–82. http://dx.doi.org/10.2466/pr0.1994.74.3c.1280.
Full textAbstract:
The present study examined differences related to gender and hierarchical position in interpersonal relations in a public-sector organisation called Bharat Petroleum Corporation, Ltd. Data were collected from 100 respondents and subjected to analysis of variance. Gender differences were observed in received openness and significance and hierarchical differences in received control and expressed inclusion, openness, significance, and competence.
18
Nosov, Pavlo, Serhii Zinchenko, Andrii Ben, Yurii Prokopchuk, Pavlo Mamenko, Ihor Popovych, Vladyslav Moiseienko, and Dmytro Kruglyj. "Navigation safety control system development through navigator action prediction by data mining means." Eastern-European Journal of Enterprise Technologies 2, no. 9 (110) (April 30, 2021): 55–68. http://dx.doi.org/10.15587/1729-4061.2021.229237.
Full textAbstract:
Taking into account current trends in the development of ergatic maritime transport systems, the factors of the navigator’s influence on vessel control processes were determined. Within the framework of the research hypothesis, to improve navigation safety, it is necessary to apply predictive data mining models and automated vessel control. The paper proposes a diagram of the ergatic vessel control system and a model for identifying the influence of the navigator “human factor” during navigation. Within the framework of the model based on the principles of navigator decision trees, prediction by data mining means is applied, taking into account the identifiers of the occurrence of a critical situation. Based on the prediction results, a method for optimal vessel control in critical situations was developed, which is triggered at the nodes of the navigator decision tree, which reduces the likelihood of a critical impact on vessel control. The proposed approaches were tested in the research laboratory “Development of decision support systems, ergatic and automated vessel control systems”. The use of the Navi Trainer 5,000 navigation simulator (Wärtsilä Corporation, Finland) and simulation of the navigation safety control system for critical situations have confirmed its effectiveness. As a result of testing, it was determined that the activation of the system allowed reducing the likelihood of critical situations by 18–54 %. In 11 % of cases, the system switched the vessel control processes to automatic mode and, as a result, reduced the risk of emergencies. The use of automated data mining tools made it possible to neutralize the negative influence of the “human factor” of the navigator and to reduce the average maneuvering time during vessel navigation to 23 %
19
Scribante, Andrea, Marco Bollardi, Marco Chiesa, Claudio Poggio, and Marco Colombo. "Flexural Properties and Elastic Modulus of Different Esthetic Restorative Materials: Evaluation after Exposure to Acidic Drink." BioMed Research International 2019 (February 4, 2019): 1–8. http://dx.doi.org/10.1155/2019/5109481.
Full textAbstract:
Background. Acidic beverages, such as soft drinks, can produce erosion of resin composites. The purpose of the present study was to investigate mechanical properties of different esthetic restorative materials after exposure to acidic drink. Methods. Nine different composites were tested: nanofilled (Filtek Supreme XTE, 3M ESPE), microfilled hybrid (G-ænial, GC Corporation), nanohybrid Ormocer (Admira Fusion, Voco), microfilled (Gradia Direct, GC Corporation), microfilled hybrid (Essentia, GC Corporation), nanoceramic (Ceram.X Universal, Dentsply De Trey), supranano spherical hybrid (Estelite Asteria, Tokuyama Dental Corporation), flowable microfilled hybrid (Gradia Direct Flo, GC Corporation), and bulk fill flowable (SureFil SDR flow, Dentsply De Trey). Thirty specimens of each esthetic restorative material were divided into 3 subgroups (n=10): specimens of subgroup 1 were used as control, specimens of subgroup 2 were immersed in 50 ml of Coca Cola for 1 week, and specimens of subgroup 3 were immersed in 50 ml of Coca Cola for 1 month. Flexural strength and elastic modulus were measured for each material with an Instron Universal Testing Machine. Data were submitted to statistical analysis. Results. After distilled water immersion, nanofilled composite showed the highest value of both flexural strength and elastic modulus, but its flexural values decreased after acidic drink immersion. No significant differences were reported between distilled water and acidic drink immersion for all other materials tested both for flexural and for elastic modulus values. Conclusions. Even if nanofilled composite showed highest results, acidic drink immersion significantly reduced flexural values.
20
Gong, Ting, and Hui Yan. "Research on Two-Speed CAN BUS Technique in Automobile Manufacturing System." Applied Mechanics and Materials 214 (November 2012): 591–95. http://dx.doi.org/10.4028/www.scientific.net/amm.214.591.
Full textAbstract:
In order to enhance the automation and safety of vehicle, the application of computer technology to the automobile control system has increasingly become a trend. In this paper, the TMS320LF2407 produced by TI Corporation is employed as the microprocessor controller and gateway, which constitute a two-speed CAN communication and control network designed for the automobile control system. Then a specific design plan of application of Two-Speed BUS in automobile control system is elaborated. Through this two-speed CAN bus technique in the vehicle control system, the overall system data sharing is achieved and the performance and security of vehicle control system are improved.
21
Li, Yan Juan. "Study on Realtime Information Integrating System Orienting Enterprise." Applied Mechanics and Materials 44-47 (December 2010): 1713–18. http://dx.doi.org/10.4028/www.scientific.net/amm.44-47.1713.
Full textAbstract:
To integrate the information of equipment and plant in designing, achieve the whole information of plant production course and share the data is the only way in corporation management information. The method and key technology of integration from local control layer to management layer were introduced. The application of Web Service was presented, and the detail development process for a plant was expatiated.
22
Mbo, Mbako, and Charles Adjasi. "Performance of SOEs: evidence on Botswana Telecommunications Corporation." International Journal of Social Economics 44, no. 7 (July 10, 2017): 960–79. http://dx.doi.org/10.1108/ijse-01-2016-0005.
Full textAbstract:
Purpose The purpose of this paper is to investigate fundamental performance drivers in a state-owned enterprise (SOE) in the context of organizational theories. Design/methodology/approach This paper is based on a case analysis investigating how several factors, considered in the context of organizational theories, have combined to influence sustained performance at the Botswana Telecommunications Corporation (BTC). The study analyses both quantitative and qualitative data pertaining to an 18-year period from 1995 to 2012. Findings The paper supports the widely held view that agency and resource-based theories explain good performance, but challenges the popular view that political influence is always self-interest driven. A concept of positive public choice, under which such influence is driven by stakeholder interests and sustainability emerges. The case reveals that a selective approach to stakeholders defined how BTC crafted its good performance in a politically conducive environment. Practical implications Based on the research findings, a framework unifying political intervention with stakeholder interests needs to be developed and formalized with a link to SOE objectives. The framework would have clear performance measures linked to it, adequately monitored under a governance structure constituted from well-incentivized boards and managers with adequate strategic corporate resources under their control. The paper proposes such a framework. Originality/value The paper reveals an unexplored area of potential research, i.e. a positive public choice perspective under which societal interests are modeled with enterprise sustainability through political processes often blamed for poor performance.
23
Palmås, Karl. "Predicting what you'll do tomorrow: Panspectric surveillance and the contemporary corporation." Surveillance & Society 8, no. 3 (September 9, 2010): 338–54. http://dx.doi.org/10.24908/ss.v8i3.4168.
Full textAbstract:
In an economy of rapidly mutating consumer preferences, new forms of surveillance have been developed within contemporary business. Increasingly, so-called “panspectric” techniques of predicting consumption choices, and tracking the shifting customer desires, are proving crucial for corporations trying to compete on the market place. Using the Deleuzian concepts of “assemblage” and “societies of control” as a point of departure, this paper explores how a new societal “diagram” is currently actualised in the marketing practices of contemporary corporations. This diagram emerges as the result of the concatenation of technological architectures (increased digital logging of everyday behaviours and data mining) and new perspectives on the human constitution; perspectives that dovetail nicely with contemporary social theory. Thus, social scientists are already complicit in the emergence of new modes of marketing-cum-surveillance.
24
Hart, David M. "From “Ward of the State” to “Revolutionary Without a Movement”: The Political Development of William C. Norris and Control Data Corporation, 1957–1986." Enterprise & Society 6, no. 2 (June 2005): 197–223. http://dx.doi.org/10.1017/s1467222700015317.
Full textAbstract:
This article traces the political development of the Control Data Corporation (CDC) and its founder and chief executive officer, William C. Norris, from the firm’s formation in 1957 until his departure from its leadership in 1986. Norris was entrepreneurial in his political strategy, taking large risks to pursue what he perceived to be large opportunities in such areas as antitrust, trade policy, and poverty alleviation. Indeed, his perceptions of these opportunities often diverged substantially from those of others in the computer industry and the broader corporate and policy communities. The article links these differences to Norris’s personal circumstances, the business situation of CDC, and the broader political currents of the times. The experiences of Norris and CDC suggest that business historians need a more expansive and flexible conception of the political attitudes and behavior of business leaders and of the business-government relationship in the United States.
25
Kinsey, John S. "Dust control handbook, by Vinit Mody and Raj Jakhete, Noyes Data Corporation, Park Ridge, NJ, 1988, 203 pages, U.S. List Price: $39.00." Environmental Progress 9, no. 1 (February 1990): F7. http://dx.doi.org/10.1002/ep.670090105.
Full text
26
Shetty, Sucharitha, B. Dinesh Rao, and Srikanth Prabhu. "Growth of relational model: Interdependence and complementary to big data." International Journal of Electrical and Computer Engineering (IJECE) 11, no. 2 (April 1, 2021): 1780. http://dx.doi.org/10.11591/ijece.v11i2.pp1780-1795.
Full textAbstract:
A database management system is a constant application of science that provides a platform for the creation, movement, and use of voluminous data. The area has witnessed a series of developments and technological advancements from its conventional structured database to the recent buzzword, bigdata. This paper aims to provide a complete model of a relational database that is still being widely used because of its well known ACID properties namely, atomicity, consistency, integrity and durability. Specifically, the objective of this paper is to highlight the adoption of relational model approaches by bigdata techniques. Towards addressing the reason for this in corporation, this paper qualitatively studied the advancements done over a while on the relational data model. First, the variations in the data storage layout are illustrated based on the needs of the application. Second, quick data retrieval techniques like indexing, query processing and concurrency control methods are revealed. The paper provides vital insights to appraise the efficiency of the structured database in the unstructured environment, particularly when both consistency and scalability become an issue in the working of the hybrid transactional and analytical database management system.
27
Ahmadi, Noor Roufiq, Maesti Mardiharini, and Chandra Indrawanto. "Pineapple farmer corporation development strategy in Central Lampung District, Indonesia." E3S Web of Conferences 306 (2021): 02055. http://dx.doi.org/10.1051/e3sconf/202130602055.
Full textAbstract:
Central Lampung is a pineapple production center that supplies fresh pineapples for national demand. On the other hand, Sub-optimal production and marketing, which are still controlled by middlemen, are the main problems in pineapple development. The research aims to identify the potential and needs for innovation, and to formulate a strategy for developing pineapple based on farmer cooperations. The research was conducted from September 2020 in Punggur District, Lampung. Data collection was carried out through a Focus Group Discussion (FGD) and in-depth interviews with local champions. The SWOT approach as well as IFE and EFE analysis have been determine to the best strategy. The results showed that farmers used the Queen variety from 1970, so that, the quality production decreased. The innovations needed are mainly related to cultivation (irrigation, crop rotation, control of pests). The existence of Farmer-Owned Enterprises in collaboration with BUMDES has the potential to be reactivated into a farmer corporation. The IFE and EFE analysis showed that the strategy that needs to be taken is the development strategy (SO strategy). Therefor, Policies that need to be followed is increasing: The role and skills of extension workers; and the role of farmers group or corporation in pineapple production and marketing.
28
Lonial, Sagar, Michael Amatangelo, Rakesh Popat, Monique C. Minnema, Jeffrey A. Zonder, Jeremy Larsen, Albert Oriol Rocafiguera, et al. "Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)." Blood 134, Supplement_1 (November 13, 2019): 3119. http://dx.doi.org/10.1182/blood-2019-124298.
Full textAbstract:
Introduction: Despite advances in treatment strategy, multiple myeloma (MM) remains a challenging, incurable disease as patients (pts) often relapse. Here we describe preclinical data of a novel cereblon (CRBN) E3 ligase modulatory compound (CELMoD), iberdomide (IBER; CC-220), as well as clinical and translational data from a current phase 1/2 clinical trial (NCT02773030). These data support a differentiated profile for IBER from immunomodulatory agents (IMiD agents), and development of IBER as a foundation of combination therapy for the treatment of relapsed/refractory MM (RRMM). Methods: Preclinical analyses were performed on pomalidomide (POM)-sensitive and acquired-resistant MM cell lines and peripheral blood mononuclear cells from healthy volunteers. Eligible pts enrolled on the clinical trial had RRMM and had received ≥ 2 prior regimens, containing at least an IMiD agent and proteasome inhibitor (PI), and had experienced disease progression within 60 days of last MM therapy. Escalating doses of IBER were given on Days 1-21, in combination with dexamethasone (DEX; 40 mg; 20 mg in pts aged > 75 years) on Days 1, 8, 15, and 22, of each 28-day cycle. Immunohistochemistry (IHC) data on CRBN, Ikaros, Aiolos, and ZFP91 expression was obtained from pt bone marrow specimens at screening and at Cycle 2, Day 15. Immune profiling was evaluated by flow cytometry of peripheral blood at Cycle 1, Day 1 and Cycle 2, Day 15. Primary objectives were to evaluate maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety, and preliminary efficacy. Results: Preclinically, IBER exhibited potent tumoricidal anti-MM and immunostimulatory activity. IBER was more potent than lenalidomide (LEN) or POM in overcoming the immunosuppressive activity of bortezomib (BORT), inducing a more than twofold increase in T cell proliferation in the presence of BORT. IBER also enhanced the antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of daratumumab (DARA), leading to deeper responses than combinations with LEN or POM. Further differentiating from both LEN and POM, IBER showed activity alone and in combination with BORT or DARA in POM-resistant MM cell lines. As of June 28, 2019, 69 pts with RRMM had received IBER + DEX. Median age was 65 years (range 33-80), and median number of prior regimens was 5 (range 2-12). Prior therapies included autologous stem cell transplantation (80%), LEN (100%), POM (70%), PIs (100%), DARA (71%) and anti-BCMA (6%), including CAR T cells. Clinical activity was observed across all dose levels with an overall response rate (ORR) of 29%, clinical benefit rate of 45%, and disease control rate of 80%. ORR was 30%, 28% and 29% in IMiD agent-refractory, DARA-refractory and Quad-class (IMiD agents/PIs/steroids/CD-38 antibodies)-refractory pts, respectively. IBER + DEX showed a favorable safety profile, with grade 3-4 neutropenia, infections, and thrombocytopenia, occurring in 29%, 25%, and 12% of pts, respectively. To date, IBER doses range from 0.3 to 1.3 mg and the MTD/RP2D has not yet been reached. Pharmacodynamic immunophenotyping changes were dose-dependent. Treatment with IBER (at doses > 0.75mg) + DEX doubled the percentage of proliferating T cells and NK cells (P < 0.001 for each) and increased activated and effector memory CD8+ and CD4+ T cells by > 50% (P < 0.01 for each subset). Pharmacodynamic changes in pt bone marrow by quantitative IHC scoring showed significant degradation of substrates (Ikaros, P = 0.006; Aiolos, P < 0.001; ZFP91, P < 0.001) and downregulation of c-myc (P = 0.027), including in pts refractory to POM and with low CRBN expression. Conclusions: IBER + DEX has shown notable clinical activity and favorable tolerability in heavily pretreated pts with RRMM, including pts refractory to prior IMiD therapy. Preclinical and translational data suggest a differentiated profile of IBER from IMiD agents in regard to activity in POM-resistant models, potency in combination with BORT and DARA, and by inducing changes in CD4+ T cells that were not observed in pts treated with POM from prior studies. Taken together, these data support a differentiated profile for IBER from IMiD agents, and the clinical development of IBER as a foundation of combination therapy for the treatment of RRMM. This study is ongoing, and includes cohorts evaluating the combinations of IBER + DEX with DARA, BORT, and carfilzomib. Updated results will be presented at the meeting. Disclosures Lonial: Karyopharm: Consultancy; GSK: Consultancy; Takeda: Consultancy, Research Funding; Celgene Corporation: Consultancy, Research Funding; Amgen: Consultancy; Genentech: Consultancy; Janssen: Consultancy, Research Funding; BMS: Consultancy. Amatangelo:Celgene Corporation: Employment, Equity Ownership. Popat:Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel, accommodations, expenses; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria; Takeda: Honoraria, Other: travel, accommodations, expenses; Janssen: Honoraria, Other: travel support to meetings. Minnema:Gilead: Honoraria; Celgene Corporation: Honoraria, Research Funding; Amgen: Honoraria; Servier: Honoraria; Jansen Cilag: Honoraria. Zonder:Alnylam: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Intellia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Caelum: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Larsen:Janssen Oncology: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Oriol Rocafiguera:Celgene Corporation: Consultancy, Speakers Bureau; Janssen: Consultancy; Amgen: Consultancy, Speakers Bureau. Rodriguez Otero:Celgene Corporation: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria; Takeda: Consultancy; BMS: Honoraria; Kite Pharma: Consultancy. Badros:Celgene Corporation: Consultancy; Amgen: Consultancy. Siegel:Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol-Myers Squibb Company: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Jagannath:Bristol-Myers Squibb: Consultancy; Janssen Pharmaceuticals: Consultancy; Karyopharm Therapeutics: Consultancy; AbbVie: Consultancy; Merck & Co.: Consultancy; Celgene Corporation: Consultancy. Bringhen:Bristol-Myers Squibb: Honoraria; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy. Gironella:Amgen: Honoraria; Janssen: Honoraria; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Kaiser:Takeda, Janssen, Celgene, Amgen: Honoraria, Other: Travel Expenses; Abbvie, Celgene, Takeda, Janssen, Amgen, Abbvie, Karyopharm: Consultancy; Celgene, Janssen: Research Funding. Cook:Janssen, Takeda, Sanofi, Karyopharm, Celgene: Consultancy, Honoraria, Speakers Bureau; Amgen, Bristol-Myers Squib, GlycoMimetics, Seattle Genetics, Sanofi: Honoraria; Celgene, Janssen-Cilag, Takeda: Honoraria, Research Funding. Gamberi:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees. Sonneveld:SkylineDx: Research Funding; Takeda: Honoraria, Research Funding; Karyopharm: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; BMS: Honoraria; Amgen: Honoraria, Research Funding. Nguyen:Celgene Corporation: Employment, Equity Ownership. Chen:Celgene Corporation: Employment, Equity Ownership. Homan:Celgene Corporation: Employment. Bjorklund:Celgene Corporation: Employment, Equity Ownership. Wang:Celgene Corporation: Employment, Equity Ownership. Pierceall:Celgene Corporation: Employment, Equity Ownership. Bensmaine:Celgene Corporation: Employment, Equity Ownership. Thakurta:Celgene: Employment, Equity Ownership. Peluso:Celgene Corporation: Employment. Van De Donk:Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees, Research Funding; Servier: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AMGEN: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees.
29
Boyd, Jeffrey A., Bruce L. Levine, Kathrin Jinivizian, Margit A. Jeschke, Megan M. Suhoski Davis, Zhaohui Zheng, Daniel Stark, Liza Loidolt, Christopher H. Keir, and Patricia A. Wood. "Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry." Blood 126, no. 23 (December 3, 2015): 3100. http://dx.doi.org/10.1182/blood.v126.23.3100.3100.
Full textAbstract:
Abstract Introduction: Use of chimeric Antigen Receptor (CAR) targeting CD19 (CTL019) as a cell-based immunotherapy has been reported to have positive results with high complete response rates in hematological malignancies, including relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas (NHL). In all the studies reported thus far with CTL019, the cell therapy was processed in an academic center (University of Pennsylvania). For large-scale manufacturing of CTL019 and more widespread distribution to patients and physicians, a focus on scalability to meet demands is critical. Here we report the outcomes from successful transfer of CTL019 processing technology from academia to our large-scale GMP facility. Methods & Results: The focus of effective transfer included areas of manufacturing process and analytical technology to consistently manufacture CTL019 with scale-up capabilities. Through strong collaboration of diverse technology transfer team participants from academia, GMP production, Technical development, Quality Assurance and Regulatory, we developed a step-based approach for process transfer. After gathering data from the academia process we made improvements to further enhance control and consistency of the process by implementing key Quality Systems elements (e.g., batch record, change control, process SOPs). Areas of improvement included closing of process steps through customized consumable and equipment solutions; replacing some manual processes with automation solutions and developing a new quantitation method for the expression of the CTL019 transgene. Initial production and release testing results and experience were gained by utilizing healthy donor starting material for manufacturing the cell product in our large scale GMP production facility. Patient-derived autologous CTL019 for treatment of pediatric patients with r/r ALL enrolled in a US-based, multicenter, phase II clinical trial have now been processed in the industry setting. Shipping logistics of the cryopreserved products (apheresis and CTL019) have been established. The cell expansion growth curves and release criteria on the cell products obtained in this large scale manufacturing facility were similar to those obtained at the academic facility. Conclusions: Leveraging a proven step-wise industry transfer process to capture academic experience along with extensive collaborative training and strong analytics led to this successful CAR cell therapy process transfer from academia to industry. This resulted in CTL019 cell expansion growth curves from our process that were similar to those observed from academia, which we anticipate will provide for global scalability. Figure 1. Figure 1. Disclosures Boyd: Novartis Pharmaceuticals Corporation: Employment. Levine:Novartis: Patents & Royalties, Research Funding. Jinivizian:Novartis Pharmaceuticals Corporation: Employment. Jeschke:Novartis Pharmaceuticals Corporation: Employment. Suhoski Davis:Novartis: Patents & Royalties. Zheng:Novartis: Patents & Royalties. Stark:Novartis Pharma AG: Employment. Loidolt:Novartis Pharmaceuticals Corporation: Employment. Keir:Novartis Pharmaceuticals Corporation: Employment. Wood:Novartis Pharmaceuticals Corporation: Employment.
30
Byrne, Shannon, Brian Clifford, Walter Simmons, Jan Depner, Barbara Reed, Jenny Moestikiwati, and Gail Smith. "Processing Data for Seafloor Mapping: Integration and Metrics." Marine Technology Society Journal 35, no. 4 (December 1, 2001): 20–32. http://dx.doi.org/10.4031/002533201788058017.
Full textAbstract:
Today's state-of-the-art hydrographic survey instrumentation produces higher resolution and more densely sampled measurements than were available in the past. This supports improvements in the definition of seafloor features and characteristics, however, it also places more stringent requirements on the systems used to process seafloor survey data. In shallow water environments bathymetric sampling rates can exceed 4000 soundings per second and data from Digital Side-Scan Sonar Systems can exceed 1 Gb/hr. In support of the Second International Conference on High-Resolution Surveys in Shallow Water, and working in cooperation with Reson Inc., Goleta, Ca., and the University of New Hampshire's Center for Coastal and Ocean Mapping (CCOM), Science Applications International Corporation (SAIC), Newport, RI conducted a survey of the conference common data set test area in Portsmouth Harbor using a Reson 8125 dual-head sonar system. The acquired data were made available as part of the conference common dataset. An area-based approach to data cleaning, including the use of an automated filter for spike detection, is presented. Resource and effort metrics associated with the processing of samples from the common data set are provided. This includes corrector application, data cleaning, validation, and quality control. Results from the area-based approach are compared with results from a traditional line-oriented approach. Three bathymetric datasets from Portsmouth Harbor are compared and the results reported.
31
Swords, Ronan T., Kevin R. Kelly, Devalingam Mahalingam, Stephen C. Cohen, Larry J. Miller, Thomas E. Philbeck, Sander O. Hacker, Cathy J. Spadaccini, Andrew Brenner, and Francis J. Giles. "Use of a New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Excellent Specimens Quickly and Efficiently." Blood 114, no. 22 (November 20, 2009): 4544. http://dx.doi.org/10.1182/blood.v114.22.4544.4544.
Full textAbstract:
Abstract Abstract 4544 Background The importance of bone marrow aspiration and biopsy in the evaluation of hematopoietic and non-hematopoietic disorders is well established. Recently, a new FDA-cleared battery powered bone marrow biopsy system was developed to allow operators access to the bone marrow space quickly and efficiently. Aims The first aim of this study was to evaluate the quality of core specimens using the new powered device compared to specimens obtained using the traditional manual technique in a swine model. The second aim was to evaluate the safety and efficacy of the device in patients presenting for outpatient hematology clinic visits. Materials and Methods For the pre-clinical evaluation of the device, three anesthetized pigs were used for the study. The powered device (OnControl, Vidacare Corporation, San Antonio, TX, USA) was comprised of a battery powered driver and needle set. The manual device used was a T-Handle Jamshidi bone marrow biopsy needle (Cardinal Health, Dublin, OH, USA). Core biopsy samples obtained were assessed for length and sample quality and then submitted for analysis to a pathologist blinded to the device used. The clinical evaluation of the device was conducted in accordance with practice guidelines and directions for use. Data collection included insertion success, time from insertion to removal, specimen quality, operator satisfaction with control/function of the device and overall operator satisfaction based on a scoring system (0-5; 0=totally unacceptable, 5=outstanding). Results Twenty six samples were collected from the swine model (19 samples using the powered device and 9 using the manual technique). No cellular artifact or thermal damage was reported in any of the samples obtained. The mean lengths for samples obtained using the powered and manual techniques were respectively 19.4mm±1.6mm and 18.6mm±5.3mm. For the clinical evaluation of the device, 16 patients were recruited from 2 centers. Mean insertion time was 11.25±3.39 seconds and mean time from needle contact with skin to needle removal was 38.5±13.94 seconds. No complications were reported. Five operators rated the overall use of the device as outstanding in 75% of cases. Conclusions In this study, the manual and powered samples were equivalent in specimen quality. The powered device however, captured longer biopsies when compared to the manual technique. In the patients evaluated, the device was easy to use as well as being safe and effective. The mean procedural time was significantly faster than previously reported with a manual technique. A randomized study of the powered device compared to the manual technique is underway. Disclosures: Swords: Vidacare Corporation: Research Funding. Kelly:Vidacare Corporation: Research Funding. Mahalingam:Vidacare Corporation: Research Funding. Cohen:Vidacare Corporation: Membership on an entity's Board of Directors or advisory committees, Research Funding. Miller:Vidacare Corporation: Employment, Equity Ownership. Philbeck:Vidacare Corporation: Employment, Equity Ownership. Brenner:Vidacare Corporation: Consultancy, Research Funding. Giles:Vidacare Corporation: Research Funding.
32
Xu, Zhi Ling, Fei Biao Li, and Zhi Fei Li. "Based on Heating Network Load Forecasting of Steam Measurement Monitoring System." Advanced Materials Research 347-353 (October 2011): 103–6. http://dx.doi.org/10.4028/www.scientific.net/amr.347-353.103.
Full textAbstract:
With the development of urban central heating, remote monitoring technology plays an important role in the heating network monitoring, control and management. The system, which uses the remote transmission manner of data radio, collects steam parameters from every steam-using corporation and sends them to the monitoring center of thermoelectricity plant, then analyses and disposes the data through the monitoring software of LabVIEW, brings forward a heating network load forecasting method based on wavelet and Neural network, decomposes load sequence to use wavelet packet, processes Elman network model training for subsequence, and recomposes the load forecasting results.
33
Kim, Gyu-Sik, Youn-Suk Son, Jai-Hyo Lee, In-Won Kim, Jo-Chun Kim, Joon-Tae Oh, and Hiesik Kim. "Air Pollution Monitoring and Control System for Subway Stations Using Environmental Sensors." Journal of Sensors 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/1865614.
Full textAbstract:
The metropolitan city of Seoul uses more energy than any other area in South Korea due to its high population density. It also has high emissions of air pollutants. Since an individual usually spends most of his/her working hours indoors, the ambient air quality refers to indoor air quality. In particular, PM10concentration in the underground areas should be monitored to preserve the health of commuters in the subway system. Seoul Metro and Seoul Metropolitan Rapid Transit Corporation measure several air pollutants regularly. In this study, the accuracy of an instrument for PM measurement using the light scattering method was improved with the help of a linear regression analysis technique to continuously measure thePM10concentrations in subway stations. In addition, an air quality monitoring system based on environmental sensors was implemented to display and record the data of PM10, CO2, temperature, and humidity. Through experimental studies, we found that ventilation fans could improve air quality and decrease PM10concentrations in the tunnels effectively by increasing the air flow rate.
34
Song, Degang, Michael H. Swartz, Steve G. Biesecker, Fernando Borda, Rutul R. Shah, Peter Emtage, William G. Wierda, Laurence J. N. Cooper, and Tim Chan. "Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33." Blood 128, no. 22 (December 2, 2016): 4058. http://dx.doi.org/10.1182/blood.v128.22.4058.4058.
Full textAbstract:
Abstract Relapsed acute myeloid leukemia (AML) is an aggressive disease with very poor outcomes. Redirection of T-cell specificity via chimeric antigen receptor (CAR) has shown promising anti-tumor activity in clinical trials, particularly for B cell linage malignancies. CD33 is a transmembrane protein expressed on normal and malignant myeloid-derived cells as well (as on subsets of activated T cells and NK cells). Since this protein is commonly expressed on AML cells, we sought to evaluate the efficacy of targeting AML with CD33-specific CAR-T cells. We generated a lentiviral construct to co-express CD33-specific CAR and a kill switch based on a tag derived from the epidermal growth factor receptor. The latter allows for the conditional elimination of CAR-T cells in vivo. Following transduction of primary T cells, we confirmed CAR and kill switch co-expression by flow cytometry and western blot analyses. Elimination of genetically modified T cells was demonstrated using the clinically-available antibody, cetuximab. CD33 CAR-T cells demonstrated specific cytotoxicity to CD33+ target cell lines. CD33 CAR-T cells were also activated to produce IFNg, TNF, and IL-2 cytokines in response to CD33+ target cells. Furthermore, adoptive transfer of CD33 CAR-T in immunocompromised (NSG) mice bearing established CD33+(CD19neg) AML (MOLM-13) tumor resulted in reduction of tumor burden and improvement of overall survival, compared to control mice receiving CD19 CAR-T cells or no immunotherapy (Figure). Sampling of blood demonstrated the persistence of the CD33 CAR-T cells with no detection of AML (MOLM-13) tumor cells. These pre-clinical data demonstrate the effectiveness of CD33 CAR-T cells in targeting CD33+ AML tumor cells and provide a rationale for future clinical evaluation in AML patients with unmet medical need. Disclosures Song: Intrexon Corporation: Employment, Equity Ownership. Swartz:Intrexon Corporation: Employment, Equity Ownership. Biesecker:Intrexon Corporation: Employment, Equity Ownership. Borda:Intrexon Corporation: Employment. Shah:Intrexon Corporation: Employment, Equity Ownership. Wierda:Genentech: Research Funding; Gilead: Research Funding; Abbvie: Research Funding; Novartis: Research Funding; Acerta: Research Funding. Cooper:MD Anderson Cancer Center: Employment; Intrexon: Equity Ownership; Sangamo BioSciences: Patents & Royalties; Targazyme,Inc.,: Equity Ownership; City of Hope: Patents & Royalties; ZIOPHARM Oncology: Employment, Equity Ownership, Patents & Royalties; Miltenyi Biotec: Honoraria; Immatics: Equity Ownership. Chan:Intrexon Corporation: Employment, Equity Ownership.
35
Hart, D. M. "From "Ward of the State" to "Revolutionary Without a Movement": The Political Development of William C. Norris and Control Data Corporation, 1957-1986." Enterprise and Society 6, no. 2 (June 1, 2005): 197–223. http://dx.doi.org/10.1093/es/khi029.
Full text
36
Saydam, Guray, Ibrahim C. Haznedaroglu, Leylagul Kaynar, Akif S. Yavuz, Ridvan Ali, Birol Guvenc, Olga M. Akay, et al. "Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia." Blood 122, no. 21 (November 15, 2013): 2742. http://dx.doi.org/10.1182/blood.v122.21.2742.2742.
Full textAbstract:
Abstract Introduction Nilotinib, a more potent and selective drug than imatinib, was approved by the FDA and EMA initially for the treatment of chronic and accelerated phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) patients resistant or intolerant to prior therapy including imatinib and subsequently for the treatment of newly-diagnosed Ph+ CML patients in the chronic phase (CML-CP). The aim of the present study was to investigate efficacy and safety profile of nilotinib in a Turkish population of newly-diagnosed Ph+ CML-CP patients and to evaluate the effects of these results on prognosis according to current treatment guidelines. Methods The study was planned as a multicenter, open-label, one-arm phase II clinical trial. All patients were planned to be treated with nilotinib (AMN107, Tasigna®) 300 mg BID for 24 months. Herein, efficacy results of the patients who completed the first year of the study are presented. Results Of the 112 patients included in the study, data for 94 patients who completed 12 months of the study up to April 29, 2013 were analyzed. Of these 94 patients, 16 were excluded within this period and 78 completed the first year of the study within the median 371 days (range, 339-401 days) or median 12.4 months (range, 11.3-13.4 months). General characteristics of the patients are presented in Table 1. Treatment-related characteristics of the patients are presented in Table 2. Data are presented as mean±standard deviation or number (%), where appropriate. MMR (Major molecular rate): BCR-ABL/control gene ratio of ≤%0.1 measured by RQ-PCR as % CCyR (Complete cytogenetic response): Patients with 0% Ph+ metaphases Cumulative MMR rates at 3rd, 6th 9th, and 12th months of the patients are shown in Figure 1. Conclusions According to the results of interim analysis of this first prospective CML study conducted on Turkish population, the cumulative MMR rate by 12th month (primary endpoint) (61.7%) appears to be similar to that of the ENESTnd study. From the 3rd month, rapid and increasing MMR rates were reported and median time to MMR was 6.5 months. At both 6th and 12th month, high CCyR rates (both 90.5%) were also established. At all landmark evaluations, most of the patients rapidly achieved high rates of cytogenetic and molecular responses to nilotinib assessed by both 2009 and 2013 ELN optimal response criteria, and only one patient had disease progression. These results suggest that more rapid and greater efficacy was achieved with nilotinib during the 1st year of the study in comparison to historical data with imatinib and that nilotinib might improve short-term responses when started in the first-line setting. The rate of patients with BCR-ABL ≤10% at 3rd month, which is very important according to the current treatment guidelines, was 86.2%.The results of the present study revealed that efficacy of nilotinib, which is a licensed alternative for the treatment of newly diagnosed Ph+ CML-CP in Turkey, might provide a new standard of treatment. Disclosures: Saydam: Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Novartis Pharmaceuticals Corporation, Turkey: Consultancy, Membership on an entity’s Board of Directors or advisory committees. Haznedaroglu:Novartis Pharmaceuticals Corporation, Turkey: Honoraria, Research Funding. Yavuz:Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees. Ali:Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees. Guvenc:Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees. Sonmez:Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees. Akkaynak:Novartis Pharmaceuticals Corporation, Turkey: Employment. Dag:Novartis Pharmaceuticals Corporation, Turkey: Employment.
37
Kontou, Eleftheria, Yafeng Yin, and Ying-En Ge. "Cost-Effective and Ecofriendly Plug-In Hybrid Electric Vehicle Charging Management." Transportation Research Record: Journal of the Transportation Research Board 2628, no. 1 (January 2017): 87–98. http://dx.doi.org/10.3141/2628-10.
Full textAbstract:
This study explored two charging management schemes for plug-in hybrid electric vehicles (PHEVs). The PHEV drivers and the government were stakeholders who might have preferred different charging control strategies. For the former, a proposed controlled charging scheme minimized the operational cost during PHEV charge-depleting and sustaining modes. For the latter, the research minimized monetized carbon dioxide emissions from electricity generation for the PHEVs charging, as well as tailpipe emissions for the portion of PHEV trips fueled by gasoline. Hourly driving patterns and electricity data were leveraged. Both were representative of each of the eight North American Electric Reliability Corporation regions to examine the results of the proposed schemes. The model accounted for drivers’ activity patterns and charging availability spatial and temporal heterogeneity. The optimal charging profiles confirmed the differing nature of the objectives of PHEV drivers and the government; cost-effective charge should occur early in the morning, while ecofriendly charge should be late in the afternoon. Each control’s trade-offs between operation cost and emission savings are discussed for each North American Electric Reliability Corporation region. The availability of workplace and public charging was found to affect the optimal charging profiles greatly. Charging control is more efficient for drivers and government when PHEVs have greater electric range.
38
Singh, D., S. Mondal, and R. S. Hooda. "GREEN INDEXING OF HISAR MUNICIPAL CORPORATION USING GEOSPATIAL TECHNIQUES." ISPRS - International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences XLII-5 (November 27, 2018): 921–27. http://dx.doi.org/10.5194/isprs-archives-xlii-5-921-2018.
Full textAbstract:
<p><strong>Abstract.</strong> Urban Green Space (UGS) enhances the structure of the landscape of a city. It provides economic, social and health benefits to the inhabitants. Rapid urbanization and increase in population has put extreme pressure on urban green spaces. Therefore, mapping of urban green spaces is important to facilitate the urban planning sustainably. This study has been taken up to map the UGS in the Hisar Municipal Corporation (HMC) area of Haryana State constituting an area of 4197.32<span class="thinspace"></span>ha using high resolution LISS-IV data of November, 2017. Three different methods namely (a) Onscreen Digitization (b) Support Vector Machine-based classification (SVM) and (c) Multi Resolution Segmentation (MRS) have been tested to extract the green spaces. The onscreen digitization method has been considered as best method as compared to SVM and MRS because of the intervention of human mind and full control on manual editing. The SVM under estimated the green space for HMC with average relative deviation of 15%. However, it extracted the green area precisely without mixing of open spaces. MRS have given good results in terms of total area (relative deviation was 5%), however, spatial distribution of green spaces have been mixed with open spaces. The study identified the green index of HMC and suggested the suitability and sustainability of the city based on World Health Organization (WHO) defined standards. Green space for Hisar Municipal Corporation was 1690.96<span class="thinspace"></span>ha with average urban green space index of 0.40. Per capita green cover for HMC was 9.69<span class="thinspace"></span>m<sup>2</sup>/inhabitant, which is as per the standard reported by WHO i.e. 9<span class="thinspace"></span>m<sup>2</sup>/inhabitant. Further study may suggest some other algorithm for better results and automatic green space extraction.</p>
39
Weisel, Katja, Dan T. Vogl, Michel Delforge, Kevin Song, Meletios Dimopoulos, Jamie Cavenagh, Cyrille Hulin, et al. "Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)." Blood 124, no. 21 (December 6, 2014): 1326. http://dx.doi.org/10.1182/blood.v124.21.1326.1326.
Full textAbstract:
Abstract Introduction: Multiple myeloma (MM) is an incurable hematologic condition that is associated with high Tx costs. Resource consumption is driven by hospitalization and medical utilization, which is highest during periods of uncontrolled disease, such as after diagnosis and during relapses (De Portu 2013). In the pivotal phase 3 FIRST trial, continuous Tx with lenalidomide plus low-dose dexamethasone (Rd) was compared with fixed-duration Rd (Rd18) or fixed-duration combination Tx with melphalan, prednisone, and thalidomide (MPT), each for 18 months (mos), in NDMM pts who were ineligible for stem cell transplantation. Continuous Rd extended progression-free survival (PFS) and overall survival (interim analysis) vs. MPT. However, it is still unclear whether extending Tx duration with Rd adversely affects healthcare resource utilization. This analysis quantifies the rates of hospitalizations and medical utilization with continuous Rd over time based on data collected in the FIRST trial. Methods: The FIRST trial (N = 1,623) was a pivotal multinational, randomized, open-label study with a median follow up of 37 mos. Non-protocol-driven resource-use data was collected until subjects discontinued study Tx. To assess whether continuous Rd increases healthcare resource utilization over time, the rates of resource utilization for subjects treated with continuous Rd (N = 535) were plotted for up to 48 mos. In addition, hospitalization and medical utilization rates during the Tx period (18 mos) were estimated and compared between the 2 fixed-duration Tx arms. Results: Resource utilization amongst pts treated with continuous Rd declined over time (Figure). The annualized hospitalization rate in the first 3 mos was 3.2 times higher than the average rate for the remaining 45 mos of follow-up (2.02 vs. 0.62), and 4.2 times higher for medical utilization (5.66 vs. 1.34). After 4 years (yrs) of continuous Rd Tx, hospitalization and medical utilization rates were estimated to be 83% and 84% lower than those observed in the first 3 mos of Tx, reflecting the long-term disease control observed with continuous Rd in the FIRST trial. The highest hospitalization rates were associated with infections (0.20 per patient year), cardiovascular disorders (0.06), and respiratory and thoracic disorders (0.05). The mean (standard deviation) length of stay per admission was 14.08 (21.19) days. The highest medical utilization rates were associated with blood transfusions (0.76 interventions per patient year), general imaging procedures (0.21), respiratory and thoracic imaging procedures (0.20), and therapeutic interventions (0.09).The hospitalization rates for the fixed dose Tx arms were 0.91 (Rd18) and 0.79 (MPT) per patient year of follow-up during the Tx period of 18 mos, resulting in a rate ratio (RR) of 1.15 (1.01–1.30). The equivalent rates for medical utilization were 3.00 (Rd18) and 2.86 (MPT) medical interventions per patient year (RR = 1.05 [0.98–1.12]). Conclusions: The rates of resource utilization among pts treated with continuous Rd dropped substantially after the first 3 mos of Tx, and then gradually declined as Tx duration increased. The findings suggest that continuous Tx with Rd does not further increase resource utilization in hospitalizations and medical utilization compared to fixed-duration Tx. A comparison between the 2 fixed arms showed a 15% increase in hospitalization with Rd18 vs. MPT, and no differences in medical utilization between the 2 arms. A limitation of this analysis is that the resources were collected only while pts were receiving their respective Txs. Future analysis should include all costs generated by healthcare resources throughout pts Tx, including Tx-free intervals, and the costs associated with relapses. Figure 1: Hospitalization and medical utilization rates per patient year for patients treated with continuous Rd Figure 1:. Hospitalization and medical utilization rates per patient year for patients treated with continuous Rd Disclosures Weisel: BMS: Consultancy; Onyx: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Celgene Corporation: Consultancy, Honoraria; Noxxon: Consultancy. Off Label Use: Lenalidomide used in newly diagnosed multiple myeloma patients. Vogl:Amgen: Consultancy; Millennium/Takeda: Research Funding; GSK: Research Funding; Acetylon: Research Funding; Celgene Corporation: Consultancy. Delforge:Janssen: Honoraria; Celgene Corporation: Honoraria. Song:Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Dimopoulos:Celgene Corporation: Consultancy, Honoraria. Cavenagh:Celgene Corporation: Honoraria. Hulin:Celgene Corporation: Honoraria. Foá:Celgene Corporation: Consultancy. Oriol:Janssen: Consultancy, Speakers Bureau; Celgene Corporation: Consultancy, Speakers Bureau. Guo:Celgene Corporation: Consultancy. Monzini:Celgene Corporation: Employment, Equity Ownership. Van Oostendorp:Celgene: Employment. Ervin-Haynes:Celgene: Employment. Facon:Celgene Corporation: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
40
Venkatesh, V., R. Noraas, A. Pilchak, S. Tamirisa, K. Calvert, A. Salem, T. Broderick, M. G. Glavicic, I. Dempster, and V. Saraf. "Data Driven Tools and Methods for Microtexture Classification and Dwell Fatigue Life Prediction in Dual Phase Titanium Alloys." MATEC Web of Conferences 321 (2020): 11091. http://dx.doi.org/10.1051/matecconf/202032111091.
Full textAbstract:
Microtexture has been linked to large reductions in cold dwell fatigue (CDF) life of specific dual phase titanium alloy aeroengine components. A recently completed Metals Affordability Initiative (MAI) funded program led by Pratt & Whitney (P&W) and includes ATI Forged Products, Boeing, GE Aviation, Rolls Royce (RR), Arconic, Titanium Metals Corporation (TIMET), PCC-Wyman Gordon (PCC-WG), Scientific Forming Technologies (SFTC), Materials Resources LLC (MRL) and The Ohio State University (OSU) has developed improved techniques for the characterization of microtexured regions (MTR) in titanium billet and forgings, and integrated computational materials engineering (ICME). These methods are aimed at developing and integrating process and property modeling tools for the prediction of microtexture and fatigue life in titanium components. These characterization and fatigue life prediction tools have near-term application off ramps that will enable use for process and product development and quality control. Key results for two widely used alloys, Ti-6242 and Ti-64, will be reviewed in this paper.
41
Zhang, Li Hua, Guang Hui Li, Jiang Wei Zhao, and Bin Li. "Design and Simulation of Measurement and Control System for Silage Cylindrical Baler Based on LabVIEW." Applied Mechanics and Materials 385-386 (August 2013): 478–83. http://dx.doi.org/10.4028/www.scientific.net/amm.385-386.478.
Full textAbstract:
In order to study grasss rotary compression characteristics during round bundle process, measurement and control system for silage cylindrical baler was developed in this paper based on virtual instrument technology. The system was constituted of KM520-B silage cylindrical baler, three-phase asynchronous motor, frequency converter, sensors, data acquisition card, the LabVIEW software platform, and so on. This system can be used to acquire information such as forming chambers rotary compression pressure, motors input torque and motors power consumption. By controlling the motors input rotate speed, this paper studied the motor speed, the grass moisture content and the grass bale densitys influence on compression power consumption, grass bale forming quality and forming chambers rotary compression pressure. At the same time, this paper established simulation equipment using MAX of NI Corporation to check the built measurement and control system. The results proved that the system can well complete the set of functions.
42
Toki, Yasumichi, Katsuya Ikuta, Masayo Yamamoto, Mayumi Hatayama, Motohiro Shindo, Mikihiro Fujiya, and Toshikatsu Okumura. "Usefulness of Reticulocyte Hemoglobin Equivalent for Diagnosis of Iron Deficiency." Blood 128, no. 22 (December 2, 2016): 3621. http://dx.doi.org/10.1182/blood.v128.22.3621.3621.
Full textAbstract:
Abstract Background: Anemia is a significant worldwide health problem, and approximately 30% of world people suffer from anemia, the half of which is iron deficiency (ID). The diagnosis of anemia requires the confirmation of a decrease in hemoglobin (Hb) concentration. For the diagnosis of iron deficiency anemia (IDA), the determinations of serum ferritin and iron related parameters must be necessary even if microcytic hypochromic anemia is confirmed. With recent technological advances, the Hb content of reticulocytes can be quantified by flow cytometry. Reticulocytes exist for 1-2 days in the peripheral blood and its Hb levels might be a good index of ID.There are several markers for the assessment of Hb content in reticulocytes, including reticulocyte Hb equivalent (RET-He) and reticulocyte Hb content (CHr). RET-He, which can be measured in the same sample used for complete blood count tests by the latest automated hematology analyzers, is considered to reflect iron content in reticulocytes. If RET-He is capable of evaluating ID, it must be useful for immediate diagnosis of IDA. Therefore, we evaluated the usefulness of RET-He for determining of ID. Methods: This prospective study was approved by the ethics committee of Asahikawa Medical University (authorization numbers 1356, 1679, and 1356-3). Blood samples were obtained from 211 patients (63 males and 148 females) from 14 to 91 years old. RET-He levels were determined using an automated hematology analyzer (XN-3000® or XE-5000®, Sysmex, Kobe, Japan). Serum iron, total iron binding capacity (TIBC), serum ferritin, and biochemical data were measured using an automated chemical analyzer. Soluble transferrin receptor (sTfR) was measured by an enzyme-linked immunosorbent assay. Anemia was defined as Hb level of <12 g/dL. ID state was defined as serum ferritin level of <12 ng/mL. Patients were classified into four groups which are IDA, ID, control, and anemia without ID groups according to their Hb and serum ferritin levels (Table 1). Laboratory parameters were compared among four groups. The changes of RET-He during oral iron administration were also determined for 21 IDA patients. Results: There were 72 (14 males and 58 females), 28 (12 males and 16 females), 67 (23 males and 44 females), and 44 (14 males and 30 females) patients in the IDA, ID, control, and anemia without ID groups, respectively. As shown in Table 1, The median RET-He levels were 22.3 pg (15.1-35.6 pg), 29.7 pg (19.2-34.9 pg), 34.0 pg (25.9-38.0 pg), and 32.5 pg (19.1-46.3 pg) in the IDA, ID, control, and anemia without ID groups, respectively. Patients in not only IDA but ID groups had significantly lower RET-He levels than those in control group (p < 0.001) while there was no significant difference in RET-He levels between anemia without ID and control. RET-He correlated positively with serum iron (r = 0.654) and transferrin saturation (TSAT) (r = 0.666), and correlated negatively with TIBC (r = -0.617) and sTfR (r = -0.655). There was no correlation between RET-He and serum ferritin when all patients were included in the analysis (r = 0.287); however, analysis of groups according to their iron status revealed a positive correlation between RET-He and serum ferritin in the IDA and ID groups (r = 0.604). The area under the ROC curve (AUC) detecting ID for RET-He was 0.902, whereas AUC for serum iron, TIBC, TSAT, and sTfR were 0.889, 0.879, 0.922 and 0.821, respectively. The cutoff value of RET-He with maximal sensitivity and specificity was 30.9 pg, and the cutoff RET-He value of 28.5 pg had a specificity of >90% (sensitivity, 68%; specificity 91%). Among patients receiving iron treatments, the Hb levels increased in 14 patients, whereas Hb values decreased or did not change in 7 patients. Serum ferritin and RET-He values seemed to change in parallel with changes in Hb levels. Conclusions: In the present study, our data showed the efficacy of RET-He for diagnosis of IDA and the usefulness for monitoring drug iron administration. Because other parameters related to ID such as iron and ferritin should be measured biochemically in serum, it takes a longer time to measure serum iron and ferritin levels when compared with complete blood count tests. We would therefore suggest that measurement of RET-He might be useful to diagnose IDA because its assessment is rapid, fully automated, and can be measured in same sample used for complete blood count test. Disclosures Toki: Sysmex Corporation: Research Funding. Ikuta:Sysmex Corporation: Research Funding. Yamamoto:Sysmex Corporation: Research Funding. Hatayama:Sysmex Corporation: Research Funding. Shindo:Sysmex Corporation: Research Funding. Fujiya:Sysmex Corporation: Research Funding. Okumura:Sysmex Corporation: Research Funding.
43
Mease, P. J., A. Kavanaugh, A. Ogdie, A. F. Wells, M. Bergman, D. D. Gladman, F. Behrens, et al. "FRI0352 PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION WITH APREMILAST TREATMENT AMONG DMARD-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 771.2–772. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1530.
Full textAbstract:
Background:Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with psoriatic arthritis (PsA).1,2A question that remains is if DMARD-naive pts treated with APR have greater chances of achieving treatment targets than DMARD-experienced pts. cDAPSA is a commonly used treatment target.Objectives:To assess the predictive value of baseline (BL) clinical disease status on achieving long-term cDAPSA treatment targets at Wk 52 among DMARD-naive subjects in PALACE 4; to compare these findings vs those recently reported from the PALACE 1-3 studies in subjects with prior exposure to DMARDs; and to provide further evidence that at a group level, achievement of cDAPSA disease targets with APR is associated with no or mild articular and extra-articular disease activity by Wk 52.Methods:This post hoc analysis included subjects assigned to APR 30 mg twice daily at BL who had available cDAPSA data at BL. We calculated the probabilities of shifting across different cDAPSA categories (remission [REM]: ≤4; low disease activity [LDA]: >4 to ≤13; moderate disease activity [Mod]: >13 to ≤27; high disease activity [HDA]: >273) from BL to Wk 52. Mean values of articular and non-articular variables (e.g., PASI, SJC/TJC, MASES, dactylitis) from BL to Wk 52 were assessed by cDAPSA category achieved at Wk 52 to determine the association between achievement of targets and control of articular and non-articular manifestations. Results from the current analyses were compared with the previously reported results from PALACE 1-3.Results:A total of 175 subjects receiving APR were included; at BL, 66.3% were in HDA, 31.4% in Mod, and 2.3% were in LDA. Overall, subjects who achieved treatment targets (LDA or REM) by Wk 52 had lower levels of disease activity at BL, as shown by a lower number of swollen and tender joints and lower presence of enthesitis and dactylitis. Higher prevalence of psoriasis-involved body surface area ≥3% at BL was observed. Subjects in Mod at BL were estimated to be more than twice as likely to achieve REM or LDA at Wk 52 vs subjects in HDA at BL; for subjects in LDA at BL, the estimated probability of achieving cDAPSA treatment targets was 100% (Figure). PALACE 4 subjects with LDA and Mod at BL exhibited higher estimated probabilities of achieving treatment targets (100.0% and 61.7%, respectively) than those observed in the DMARD-experienced population of PALACE 1-3 (71.1% and 46.9%). Subjects in PALACE 4 who achieved REM or LDA by Wk 52 showed no or mild articular and extra-articular disease activity by Wk 52, similar to what was observed in the PALACE 1-3 population.4Conclusion:DMARD-naive subjects in PALACE 4 who had LDA or Mod at BL had the highest likelihood of achieving treatment targets (cDAPSA REM or LDA) by Wk 52 with continued APR treatment. Results from the current probability analyses revealed higher probability rates than those observed in the DMARD-experienced PALACE 1-3 population; control of articular and extra-articular manifestations was observed in the DMARD-naive and DMARD-experienced populations.References:[1]Wells AF, et al. Rheumatology. 2018;57:1253-63. 2. Kavanaugh A, et al. Arthritis Res Ther. 2019;21:118. 3. Machado PM. Ann Rheum Dis. 2016;75:787-90. 4. Mease PJ, et al. Arthritis Care Res. 2020 Jan 7.Disclosure of Interests:Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Arthur Kavanaugh Grant/research support from: Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB – grant/research support, Alexis Ogdie Grant/research support from: Novartis, Pfizer – grant/research support, Consultant of: AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda – consultant, Alvin F. Wells Grant/research support from: AbbVie, Celgene Corporation, Lilly – grant/research support, Consultant of: AbbVie, Alexion, Amgen, BMS, Celgene Corporation, Horizon, Lilly, Novartis, UCB – consultant, Speakers bureau: AbbVie, Alexion, Amgen, BMS, Celgene Corporation, Horizon, Lilly, Novartis, UCB – speakers bureau, Martin Bergman Shareholder of: Johnson & Johnson – stockholder, Consultant of: AbbVie, BMS, Celgene Corporation, Genentech, Janssen, Merck, Novartis, Pfizer, Sanofi – consultant, Speakers bureau: AbbVie, Celgene Corporation, Novartis, Pfizer, Sanofi – speakers bureau, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant, Frank Behrens Grant/research support from: AbbVie, Chugai, Janssen, Roche, Pfizer – grant/research support, Consultant of: AbbVie Biotest, Boehringer Ingelheim, Celgene Corporation, Chugai, Eli Lilly, Genzyme, Janssen, Novartis, Pfizer, Roche, UCB – consultant, Speakers bureau: AbbVie, Biotest, BMS, Celgene Corporation, Chugai, Eli Lilly, Genzyme, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, UCB - speaker, Sven Richter Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Michele Brunori Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Lichen Teng Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Benoit Guerette Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, Roche – grant/research support, Consultant of: AbbVie, Amgen Inc., AstraZeneca, Astro, Celgene Corporation, Celtrion, Eli Lilly, Glaxo, ILTOO, Janssen, Medimmune, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung, Sanofi, UCB – consultant, Speakers bureau: AbbVie, Amgen Inc., AstraZeneca, Astro, Celgene Corporation, Celtrion, Eli Lilly, Glaxo, ILTOO, Janssen, Medimmune, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung, Sanofi, UCB – speaker
44
Logemann, Minna, and Rebecca Piekkari. "Localize or local lies? The power of language and translation in the multinational corporation." critical perspectives on international business 11, no. 1 (March 2, 2015): 30–53. http://dx.doi.org/10.1108/cpoib-02-2014-0011.
Full textAbstract:
Purpose – The purpose of this paper is to contribute to previous research on intraorganizational power in multinational corporations (MNCs). It shows that a subsidiary manager may use language and acts of translation to resist control from headquarters and to (re)define his and his unit’s power position in a headquarters-subsidiary relationship. It also uncovers the interplay between natural languages and “company speak” as a specialized language. Design/methodology/approach – The paper is based on a single case study of a European MNC undergoing strategic change. The data were drawn from company documents, personal interviews and focus group discussions. Findings – The findings show that actors at both headquarters and in the focal subsidiary employed language and translation to exercise power over meanings; headquarters exerted control over “mindsets” and practices, while subsidiaries responded by resisting these meaning systems. The authors argue that the crossing of language boundaries offers a window onto shifting power positions and micro-politics in the MNC. Research limitations/implications – The study was limited to a single translation act in a focal headquarters-subsidiary relationship. Practical implications – From the managerial perspective, any process of communication in a multilingual context needs to be sensitive to power (re)definitions associated with language and translation. Originality/value – This study sheds light on translation as a political act and hidden activity in the MNC.
45
Carrancio, Soraya, Jennifer A. Markovics, Piu Wong, Jim Leisten, Matthew C. Groza, Heather K. Raymon, Carla Heise, Rajesh Chopra, Tom O. Daniel, and Victoria Sung. "Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin." Blood 120, no. 21 (November 16, 2012): 372. http://dx.doi.org/10.1182/blood.v120.21.372.372.
Full textAbstract:
Abstract Abstract 372 The regulation of erythropoiesis requires stem cell factor and erythropoietin (EPO) for the proliferation and survival of erythroid progenitor and early precursor cells. While recombinant EPO is widely used for treating various types of anemia, it often lacks efficacy in cases of anemia due to ineffective erythropoiesis in which immature erythroid precursors undergo apoptosis. Thus, there is an need for new therapies to treat the later stages of erythropoiesis. Members of the transforming growth factor beta (TGFβ) superfamily have been studied as potential regulators of erythropoiesis, iron regulation and globin expression. Sotatercept (ACE-011), a recombinant fusion protein consisting of the extracellular domain of the human activin receptor IIA (ActRIIA) linked to the human immunoglobulin G1 (IgG1) Fc domain, is a ligand trap which binds a number of TGFβ superfamily ligands including activin A, activin B, growth differentiation factor-11 (GDF-11) and bone morphogenetic protein-10 (BMP-10). Administration of sotatercept led to substantial increases in red cell number and hemoglobin in human subjects, but the mechanism is not fully understood. We utilized both mouse in vivo and human in vitro models to investigate the mechanism of sotatercept in promoting erythropoiesis. In order to compare the effects of RAP-011 (the murine version of sotatercept) to EPO on red blood cell (RBC) parameters, C57/Bl mice were dosed with RAP-011, EPO or control vehicle. RAP-011-treated mice had a rapid and statistically significant increase in hematocrit, hemoglobin, and RBC number in less than 72-hours. As rapidly as 24 hours after treatment, RAP-011 induced a significant increase in RNA-negative, enucleated cells in the bone marrow (BM). RAP-011 also rapidly increased BM BFU-e and CFU-e erythroid progenitors, while EPO was more effective on spleen-derived progenitors. These data suggest that RAP-011 acts primarily on both bone marrow progenitor cells and late erythroblasts to promote erythropoiesis. In order to investigate the cellular mechanism by which RAP-011 increases red blood cell parameters, we conducted a series of in vitro experiments and found no evidence to support direct effects of RAP-011 on human CD34+ cells assessed in colony formation assays and in erythroid differentiation in liquid culture. As both clinical and pharmacological findings point to a clear role for RAP-011 in stimulating RBC parameters, we hypothesized that RAP-011 effects may be mediated by accessory cells in the BM microenvironment. Human CD36+ cells, which are highly enriched for erythroid progenitors, were co-cultured with long-term BM cultures and erythroid differentiation was assessed following 6 days of culture in EPO (2U/mL)-supplemented media. At day 6 the output of these cultures was predominantly characterized as EryA (∼basophilic erythroblast) but with the addition of RAP-011 (50μM), a significant fraction of CD36+ cells matured into EryB/C cells (polychromatic/orthochromatic erythroblasts), suggesting that factors produced by BM accessory cells mediate RAP-011 erythropoietic effects and that, in contrast to EPO, RAP-011 may play a role in the latter stages of erythroblast maturation. To identify cytokines that may mediate RAP-011 effects, CD36+ cells were treated with several activin receptor IIA ligands. GDF-11 treatment significantly decreased proliferation of GPA+ cells during the differentiation process and RAP-011 effectively reversed this effect, but had no consequence on untreated cells. These data suggest that GDF-11 may mediate the erythroipoietic stimulatory effects of RAP-011. In summary, RAP-011 induced a rapid increase in RBC parameters in mice (reflected in the number of enucleated cells found in the bone marrow), likely mediated by BM accessory cells. Our data also suggest that effects of sotatercept may be mediated at least partly by GDF-11, acting as a potential negative regulator of the terminal stages of erythropoiesis. The ability of sotatercept to reverse this inhibition would lead to a rapid release of terminal erythroid cells into the circulation. These data support the rationale to develop sotatercept for the treatment of anemia and ineffective erythropoiesis, especially in patients who may not respond to EPO. Disclosures: Carrancio: Celgene Corporation: Employment. Markovics:Celgene Corporation: Employment. Wong:Celgene Corporation: Employment. Leisten:Celgene Corporation: Employment. Groza:Celgene Corporation: Employment. Raymon:Celgene Corporation: Employment. Heise:Celgene Corporation: Employment. Chopra:Celgene Corp: Employment, Equity Ownership. Daniel:Celgene Corporation: Employment. Sung:Celgene Corporation: Employment.
46
Xu, Xiaoxin, Xiulan Zhang, Teh Wei Hu, Leonard S. Miller, and Mengnan Xu. "Effects of global and domestic tobacco control policies on cigarette consumption per capita: an evaluation using monthly data in China." BMJ Open 9, no. 6 (June 2019): e025092. http://dx.doi.org/10.1136/bmjopen-2018-025092.
Full textAbstract:
IntroductionChina consumes 44% of the world’s cigarettes. Robust tobacco control measures are needed to contain the trend of increasing cigarette consumption. This paper examines the effectiveness of policy interventions introduced in China on reducing the country’s tobacco use.MethodsThe paper uses data on China’s monthly cigarette consumption per capita from January 2000 to June 2017 to estimate the impact of specific policies on China’s tobacco consumption. Tobacco consumption is calculated from monthly sales data from the China National Tobacco Corporation and demographic data from the China National Bureau of Statistics. The policies studied include the WHO Framework Convention on Tobacco Control (FCTC), national tobacco-related policy changes and two tobacco tax increases implemented in China during the study period. Segmented regression analysis is used to estimate the immediate effects of the policies studied and changes in the time trends resulted from these policy changes.FindingsThe impact of national policy changes in China is almost 20 times greater than the impact of the WHO FCTC treaty itself, and national policy changes in tobacco control are a determining factor in reversing the trend of increasing tobacco consumption in China. The 2015 tax increase, which raised retail cigarette prices, produced both immediate and trend effects, with a total incremental effect 7.8 times that of the 2009 tax increase, which did not result in higher cigarette prices for the consumer.InterpretationsTranslating global tobacco control policies into domestic policies will generate a much greater impact on reducing average cigarette consumption, and tobacco taxes that are reflected in the retail prices of cigarettes will be more effective in reducing cigarette consumption.
47
Zaman, Md Ohidur, and Tareq Mahamud Abir. "The Process of Social Exclusion of Tea Garden Workers: A Study on Sylhet City Corporation, Bangladesh." Asian Journal of Humanity, Art and Literature 5, no. 2 (December 31, 2018): 101–8. http://dx.doi.org/10.18034/ajhal.v5i2.340.
Full textAbstract:
Previous literature suggests that tea garden workers of Bangladesh are excluded from social, political and economic aspects. Therefore, this research work aimed to exploring the process of social exclusion of tea garden worker. All the tea gardens within Sylhet City Corporation have been selected as the study area and empirical data has been collected from selected respondents by Survey and In-depth interview methods. The field data show that tea garden workers are excluded in main three ways. They are deprived from social and political rights and have a very small control on their material world. Such deprivations made them incapable and create a cycle of poverty which leads them to social exclusion. Moreover, tea garden owners and managers play a peculiar role to exploit them from their basic socio-political and economic rights. In such a way, tea garden workers become excluded from the main stream people and living inhuman life.
48
Merkel, Patricia A., Hannah E. Giclas, Andrew Gibula, Gillian Andersen, Vijaya Knight, Jin-Sying Lin, Grace Castro, Jennifer Green, and Adonis Stassinopoulos. "Reinvestigation of the T-Cell Inactivation Achieved for the Prevention of TA GV HD By 2500 Gy of Gamma Irradiation, a Comparison with Pathogen Reduction." Blood 128, no. 22 (December 2, 2016): 1455. http://dx.doi.org/10.1182/blood.v128.22.1455.1455.
Full textAbstract:
Abstract Background: Transfusion Associated Graft vs. Host Disease (TA GVHD) results in high morbidity and mortality, caused by contaminating T-cells present in transfused blood products. Gamma irradiation (GI) of platelet components (PC) with a dose of 2500 cGy is the approved methodology to prevent TA GVHD in high-risk patients. That methodology has been established based on in vitro Limiting Dilution Assays (LDA) that quantify the inactivation of T-cells. The limited natural abundance of T-cells in blood products and the number of T-cells that can be reproducibly cultured in single wells have defined LDA assay sensitivity. LDA assays usually have a dynamic range of 4-5 log10. Even though that methodology has been used for decades with presumable success, cases of GVHD recognized as transfusion associated, have to be connected temporally and phenotypically to the blood product in use, in order to be characterized as such. That leaves open the possibility that some atypical cases of GVHD in blood product recipients may be miss-assigned and go unrecognized. An alternative methodology to prevent TA GVHD is the photochemical treatment of PC with amotosalen/UVA (PCT; INTERCEPTTM Blood System). PCT has replaced GI in Europe for pathoen inactivated PC for more than 10 years. In this study, we evaluated both GI and PCT on inactivation of T-cells using a highly sensitive approach that includes the use of higher numbers of PBMCs isolated by leukapheresis, and an increased number of cells cultured in a single well (107/well) by using larger wells and optimizing culture conditions. Methods: PBMCs harvested by leukapheresis from individual donors (AllCells, Alameda, CA) were spiked (106/mL) into identical units of human plasma and inactivated using either GI with 2500 cGy, PCT, or were retained as untreated control. For the LDA assay, PCT- or GI-treated cells isolated post treatment, were incubated in individual wells for 14 days in the presence of pooled allostimulator cells from 10 unrelated donors (5X106 treated with 7500 cGy) and growth stimulating factors (PHA and IL-2) under standard culture conditions. Proliferation was assessed by tritiated thymidine ([3H]TdR6.7 Ci/mmol) incorporation into PBMC, as well as by the observation of bright large clusters that were clearly observed at 40x magnification. Results: Initial experiments showed that 107PBMCs/well or 106PBMCs/well resulted in proliferation after GI at 2500 cGy, while 105 PBMCs/well did not. On the other hand, 107 PCT treated-PBMCs/well were found neither to proliferate, nor to incorporate [3H]TdRabove background. T-cell precursor frequency was measured for each donor by incubation of serial dilutions of viable PBMCs (50 - 1 /well; 12 wells per dilution) in the presence of 107 inactivated PBMCs. The experiment was repeated 10 times with PBMCs from different donors. For GI, [3H]TdR incorporation above background indicative of T-cell growth, as well as T-cell proliferating colonies were observed in 4 of 10 experiments when 106PBMCs/ well were cultured. No T-cell growth was detected by [3H]TdR incorporation when 105 GI PBMCs/well were cultured, while proliferating colonies were observed in 1 of 10 experiments. No T-cell proliferation was detected by either criterion, when 107 PCT-treated PBMCs/well were cultured. Conclusions: The accepted dose of 2500 cGy gamma irradiation for prevention of TA GVHD results in more than 4.2log10 but less than 6.2 log10 T-cell inactivation. However, it still allows the proliferation of T-cell clones from some donors. Treatment of T-cells with amotosalen/UVA results in complete inactivation of T-cells (>6.2 log10) with no break though proliferation detected. The data in this study have not been reviewed by the FDA. Disclosures Merkel: Cerus Corporation: Other: fee for service with Cerus Corporation. Giclas:Cerus Corporation: Other: fee for service with Cerus Corporation. Gibula:Cerus Corporation: Other: fee for service with Cerus Corporation. Andersen:Cerus Corporation: Other: fee for service with Cerus Corporation. Knight:Cerus Corporation: Other: fee for service with Cerus Corporation. Lin:Cerus corp: Employment. Castro:Cerus Corporation: Employment. Green:Cerus Corporation: Employment. Stassinopoulos:Cerus Corporation: Employment.
49
Mangold, Jane, Hilary Parkinson, Celestine Duncan, Peter Rice, Ed Davis, and Fabian Menalled. "Downy Brome (Bromus tectorum) Control with Imazapic on Montana Grasslands." Invasive Plant Science and Management 6, no. 4 (December 2013): 554–58. http://dx.doi.org/10.1614/ipsm-d-13-00016.1.
Full textAbstract:
AbstractDowny brome is a problematic invasive annual grass throughout western rangeland and has been increasing its abundance, spread, and impacts across Montana during the past several years. In an effort to develop effective management recommendations for control of downy brome on Montana rangeland, we compiled data from 24 trials across the state that investigated efficacy of imazapic (Plateau®, BASF Corporation, Research Triangle Park, NC) applied at various rates and timings and with methylated seed oil (MSO) or a nonionic surfactant (NIS). We ran a mixed-model ANOVA to test for main effects and interactions across application rate (70, 105, 141, 176, and 211 g ai ha−1), application timing (preemergent [PRE], early postemergent [EPOST, one- to two-leaf growth stage], and postemergent [POST, three- to four-leaf growth stage]), and adjuvant (MSO, NIS). Application timing and rate interacted to affect downy brome control (P = 0.0033). PRE imazapic application resulted in the lowest downy brome control (5 to 19%), followed by POST application (25 to 77%) and EPOST application (70 to 95%). Downy brome control remained fairly consistent across rates within application timing. Adjuvant (MSO or NIS) did not affect downy brome control (P = 0.2789). Our data indicate that POST application at 105 to 141 g ai ha−1 provides the most-consistent, short-term control of downy brome. Furthermore, applying imazapic to downy brome seedlings shortly after emergence (one- to two-leaf growth stage) provided better control than applying it to older downy brome seedlings (three- to four-leaf growth stage).
50
Tsamenyi, Mathew, Trevor Hopper, and Shahzad Uddin. "Changing control and accounting in an African gold mine." Journal of Accounting & Organizational Change 13, no. 2 (June 5, 2017): 282–308. http://dx.doi.org/10.1108/jaoc-03-2014-0017.
Full textAbstract:
Purpose The paper aims to examine accounting changes in the Ashanti Gold Corporation (AGC) in Ghana over 120 years from pre-colonialism to recent times and whether the framework of management accounting transformations in Hopper et al. (2009) is applicable. Design/methodology/approach Mixed data sources are used, namely, interviews, some observations of practices, historical documentation, company reports and research papers and theses. The results are categorised according to the periods and contextual factors in the Hopper et al. framework to test whether it matches the data collected. Findings Despotic controls with minimal management accounting but stewardship accounting to the head office in London prevailed under colonialism. Upon independence state, capitalist policies descended into politicised state capitalism. Under nationalisation, the performance of mines deteriorated, and accounting became decoupled from operations. In the early 1980s, fiscal crises forced Ghana’s government to turn to the World Bank and International Monetary Fund for loans. This period marked a gradual transformation of AGC into a foreign multinational, organised along divisional lines and currently exercises despotic control through supply chain management that renders labour precarious and is neglectful of corporate social accounting issues. Research limitations/implications The work challenges neo-classical economic prescriptions and analyses of accounting in developed countries by indicating its neglect of the interests of other stakeholders, especially labour and civil society. Accounting is important for development but the article infers other forms may better serve the public interest. Originality/value The paper tests the Hopper et al. framework with respect to a large private multinational in the commodity sector over an extended period, which differs from the case studies drawn on originally.